RECCE PHARMACEUTICALS LTD (ASX: RCE)
Health care · News and insights
Price unavailable
Latest RCE announcements
Announcement Insights
Recce Moves RECCE 327 Gel Into Phase 3 as Funding and Commercial Deals Advance
Recce reported patient dosing in Phase 3 trials of RECCE 327 Gel in Australia and Indonesia at its November 6 AGM, building on October ethics approval for an amended Australian Phase 3 study. The company also reported an exclusive Australian and New Zealand licensing deal and a non-binding Middle East term sheet; funding included A$6.4 million raised through a placement and share purchase plan, alongside expected R&D tax rebate support.
Updated 16 Nov 2026, 05:43 PM Sydney time
Sources
Application for quotation of securities - RCECleansing NoticeAGM PresentationResults of MeetingOptions ProspectusRetirement of Mr Alistair McKeough as Non-Executive DirectorQuarterly Activities/Appendix 4C Cash Flow ReportApplication for quotation of securities - RCECleansing NoticeComments
2026-11-16 · Health care
RCE: $0.370 +0.00% · MC: $113M
Recce Pharmaceuticals issued ordinary shares to partly settle fees for legal services, with no cash consideration. The shares represent a small addition to its existing share capital.
Updated 2026-11-16 17:34
Sources
Application for quotation of securities - RCECleansing NoticeComments
2026-11-06 · Health care
RCE: $0.330 +0.00% · MC: $113M
Recce Pharmaceuticals shareholders delivered a second strike against the remuneration report, with more than a quarter of votes cast opposing it, but rejected the spill resolution. The AGM presentation said patient dosing is underway in Phase 3 trials of RECCE 327 Gel in Australia and Indonesia, with an independent committee expected to review Indonesian trial data as soon as mid-November; the company also reported an exclusive Australian and New Zealand licensing deal and a non-binding Middle East term sheet.
Updated 2026-11-06 13:32
Sources
AGM PresentationResults of MeetingComments
2026-11-04 · Health care
RCE: $0.335 +0.00% · MC: $113M
Recce Pharmaceuticals director Alistair McKeough will retire after the November 6 AGM and will not seek re-election; the company has withdrawn the related resolution, and Alan Dunton will take over as Audit and Risk Committee chair. A prospectus also opens offers of unlisted options linked to the earlier placement, including up to 10 million additional options if attaching options are exercised.
Updated 2026-11-04 18:55
Sources
Options ProspectusRetirement of Mr Alistair McKeough as Non-Executive DirectorComments
2026-10-30 · Health care
RCE: $0.360 +9.09% · MC: $113M
Recce Pharmaceuticals says ethics approval is in place for an amended Australian Phase 3 study of its topical treatment for diabetic foot infections, while a Vietnamese patent expands its anti-infective intellectual property coverage. The company ended the quarter with about A$1 million in cash and expects an approximately A$7.5 million R&D tax rebate; it also reported receiving a further A$3.6 million rebate, bringing FY2025 rebates to approximately A$8.9 million. A completed share purchase plan and placement raised A$6.4 million in total, and the company issued shares under its employee incentive scheme.
Updated 2026-10-30 17:46
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportApplication for quotation of securities - RCECleansing NoticeComments
Comments